Home › Kanser sa Suso › Rhode Island
Pag-aaral pangklinika para sa Kanser sa Suso sa Rhode Island
14 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa Rhode Island.
Mga Lungsod sa Rhode Island
Opisyal na teksto ng pag-aaral (English)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- Rhode Island Hospital, Providence
Nagre-recruitPhase 3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Kent Hospital, Warwick
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Smilow Cancer Hospital - Westerly, Westerly
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06377852A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Providence
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06103864A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Rhode Island Hospital, Providence
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06492616Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Women and Infants Hospital, Providence
- Kent Hospital, Warwick
- Smilow Cancer Hospital Care Center - Westerly, Westerly
Nagre-recruitPhase 3
Edad 18 hanggang 60 · Kababaihan · Na-update Set 2, 2026 · NCT05879926ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Smilow Cancer Hospital Care center at Westerly, Westerly
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04893109Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05579366E-Mindfulness Approaches for Living After Breast Cancer
- Women and Infants Hospital, Providence
Nagre-recruitPhase 3
Edad 18 hanggang 50 · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT06748222A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Lifespan Cancer Institute - Rhode Island Hospital, Providence
Nagre-recruitPhase 2
Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
- Kent Hospital, Warwick
- at 1 pa
Nagre-recruitPhase 3
Edad 50 hanggang 70 · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT04852887EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
- Women & Infants Hospital, Providence
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT06401421SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Rhode Island and the Miriam Hospitals (Brown University Health), Providence
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 24, 2025 · NCT06974604Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.